August 17, 2017 – Cynvenio Biosystems, Inc. announced the launch of a new breast cancer monitoring study in partnership with Saint Luke’s Cancer Institute in Kansas City, Missouri. The study’s goal is to evaluate the potential for early detection of recurrent breast cancer using LiquidBiopsy and natural killer (NK) cell testing in patients at high-risk of relapse after neoadjuvant chemotherapy.
August 8, 2017 - Cynvenio launches its second generation PD-L1 expression test. The new blood test offers improved analytic performance over the company’s first generation PD-L1 test, enabling highly sensitive and specific profiling and monitoring of PD-L1 expression on lung cancer cells recovered from a simple blood draw.
July 27, 2017 – Cynvenio announced that its LiquidBiopsy rare cell and cell-free isolation platform has been deployed at Severance Hospital of the Yonsei University Health System. Located in Gangnam-Gu, Seoul, Severance Hospital is one of the oldest and largest university hospitals in South Korea and has been treating patients continuously for 130 years.
June 14, 2017 – Cynvenio announces four new distribution agreements for Cynvenio’s ClearID line of blood tests in Israel, Greece, Argentina, and South Korea.
June 4, 2017 — Download Cynvenio's poster from ASCO 2017 presenting preliminary data from the first year of our 211-patient TNBC clinical research study in a poster titled, “Use of serial multi-template liquid biopsies in triple negative breast cancer monitoring.”
June 1, 2017 – Cynvenio's LiquidBiopsy rare cell and cell-free isolation platform will be featured at the 2017 ASCO Annual Meeting at booth #23123. Also at the conference, study data collected via the LiquidBiopsy platform and supporting the utility of longitudinal monitoring of breast cancer patients will be published.
May 30, 2017 – Cynvenio to present preliminary data to support the utility of longitudinal monitoring of triple negative breast cancer patients using Cynvenio’s ClearID liquid biopsy tests at the 2017 ASCO Annual Meeting, June 2-June 6, 2017 in Chicago, Illinois.
May 16, 2017 – Cynvenio announces the release of its ClearID Lung Cancer blood test. Leveraging a highly-sensitive next-generation sequencing panel of 11 genes known to be altered in lung cancer, this new test is designed to quickly and accurately identify tumor-related genetic mutations that can be treated with targeted therapies.
April 28, 2017 – Cynvenio in partnership with TME Research announced the launch of a new neoadjuvant breast cancer monitoring (NEAT) study. The multi-center registry study will include at least 10 centers and over 150 patients to be monitored over two years with Cynvenio’s ClearID Breast Cancer blood test.
April 3, 2017 – Cynvenio today announced the immediate availability of two new antibody-based capture kits consisting of EGFR (epidermal growth factor receptor) and PSMA (prostate specific membrane antigen)
February 10, 2017 – Cynvenio Biosystems will feature its LiquidBiopsy rare cell isolation platform at Molecular Med Tri-Con 2017, February 19-24, 2017 in San Francisco.
August 11, 2016 - Article in Clinical Lab Products (CLP) magazine by Cynvenio Chief Science Officer, Paul Dempsey, PhD, discussing improvements in liquid biopsy techniques and the analysis of rare cancer-derived events present among normal cells or DNA.
July 12, 2016 - BioTech Nation interview with Dr. Paul Dempsey about Cynvenio's technology and the ongoing clinical study of women with breast cancer.
June 20, 2016 - An Interview with Paul W. Dempsey, PhD, and Paul Y. Song, MD, of Cynvenio.
May 25, 2016 - Jim Cramer interviews Thermo Fisher Scientific CEO, Marc Casper. In this segment, Casper discusses Cynvenio and LiquidBiopsy.
May 9, 2016 - Article published by Clinical Lab Products discussing the results of Cynvenio's study.
April 5, 2016 — Molecular diagnostic approaches to cancer detection and monitoring can benefit from a multiple-template strategy that analyzes DNA from circulating tumor cells (ctcDNA) and circulating cell free DNA (ccfDNA) in blood, as well as from tissue biopsies, according to new NCI-supported clinical trial published by scientists from Cynvenio Biosystems, Inc., and collaborators. The new research was published online in the journal Oncotarget.
April 1, 2016 - Genome web article highlighting a trial by researchers at Mount Sinai to evaluate the genomic profiles of ctDNA and CTCs as well as phenotypic features of CTCs in patients with triple negative breast cancer to study the relationships between the two and how they correlate with disease. The group will use Cynvenio's LiquidBiopsy microfluidic system to isolate CTCs, ctDNA, and germline DNA.
February 10, 2016 – Cynvenio announces the availability of the Concordia™ cell-free DNA (cfDNA) purification sample preparation upgrade for its multi-template analysis LiquidBiopsy® platform. When coupled with Thermo Fisher Scientific’s Ion Torrent™ next-generation sequencing (NGS) systems, Cynvenio’s workflow provides a comprehensive molecular characterization of tumor cell DNA for cancer research samples from a standard blood draw.
December 28, 2015 – Cynvenio Biosystems, Inc. and ATGen Global, a Korea-based biotech company, announced the launch of a pilot study to evaluate a new method for early detection of cancer in women who have completed treatment for triple-negative breast cancer (TNBC) and show no radiographic signs of metastases.